William Blair Issues Pessimistic Estimate for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Analysts at William Blair lowered their Q1 2025 earnings per share estimates for shares of Becton, Dickinson and Company in a note issued to investors on Friday, November 8th. William Blair analyst A. Brackmann now forecasts that the medical instruments supplier will post earnings of $3.13 per share for the quarter, down from their prior forecast of $3.17. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $13.11 per share. William Blair also issued estimates for Becton, Dickinson and Company's Q2 2025 earnings at $3.50 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $4.01 EPS and FY2025 earnings at $14.37 EPS.

A number of other analysts have also weighed in on the company. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a research note on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Buy" and a consensus target price of $283.00.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $3.22 on Monday, reaching $234.86. 587,397 shares of the company's stock traded hands, compared to its average volume of 1,399,213. The stock has a market cap of $67.88 billion, a PE ratio of 47.66, a P/E/G ratio of 1.80 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The stock has a 50-day simple moving average of $237.04 and a 200 day simple moving average of $235.10. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company's revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $3.42 earnings per share.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WR Wealth Planners LLC lifted its holdings in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier's stock worth $696,000 after purchasing an additional 42 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier's stock worth $210,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division lifted its holdings in shares of Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp grew its position in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock worth $36,000 after acquiring an additional 46 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company's payout ratio is presently 78.19%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.